Barinthus Biotherapeutics plc expects data readout for VTP-1000 before the end of 2025. Enrollment continues for the AVALON trial, with multiple ascending dose data expected in the second half of 2026. The company plans to merge with Clywedog Therapeutics Inc. to enhance its pipeline and attract new investors. The merger is set to close in the first half of 2026.

Barinthus Bio’s recent financial results show a cash balance of $75.7 million as of September 30, 2025. They reported a net loss of $14.6 million for the third quarter of 2025. Research and development expenses were $5.4 million, a decrease from the previous quarter. The company is actively seeking partners for its various programs.

The proposed merger with Clywedog is expected to strengthen the company’s position in developing disease-modifying therapies for diabetes, celiac disease, and other conditions. The combined company will operate under the name “Clywedog Therapeutics Holdings, Inc.” and trade under the ticker symbol “CLYD” on NASDAQ. The transaction is expected to provide a cash runway through 2027.

Barinthus Bio is a biopharmaceutical company focusing on immunotherapeutic candidates for autoimmunity and chronic infectious diseases. With a proprietary platform technology, the company aims to develop treatments for conditions like celiac disease. Their goal is to improve the lives of people with autoimmune diseases through innovative therapies.

Investors and security holders are advised to review the registration statement on Form S-4 for full details on the proposed transaction with Clywedog. The combined company will file with the SEC and provide important information for shareholders. No securities offering will be made without proper registration and compliance with securities laws.

The company’s financial statements for the third quarter of 2025 show a net loss of $14.6 million. Operating expenses were $15.2 million, with research and development expenses at $5.4 million. The proposed merger with Clywedog is expected to provide new opportunities for growth and development in the biopharmaceutical industry.

Read more at GlobeNewswire: Barinthus Bio Reports Third Quarter 2025 Financial Results